ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress

SAN CLEMENTE, CA / ACCESSWIRE / August 22, 2019 / ReShape Lifesciences Inc. RSLS, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be attending the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress, taking place at Ifema Palacio Municipal in Madrid, Spain, from September 3-7, 2019.

ReShape Lifesciences™ products will be represented at a booth in the exhibit hall of the conference and company representatives will be meeting with key clinical opinion leaders from multiple countries to discuss ReShape Lifesciences' focused commitment to their existing and emerging bariatric surgery technologies. Additionally, throughout the conference there will be several presentations by clinical thought leaders highlighting ReShape Lifesciences LAP-BAND® technology, including 20-year results, as well as updated presentations on the current CE Mark trial for the ReShape Gastric Vest™. Both products are laparoscopically implantable technologies that do not permanently alter a patient's anatomy

In conjunction with this conference, the Company will sponsor a special-invitation presentation for congress attendees that will review long-term data on the demonstrated safety and efficacy profiles of the LAP-BAND System. Details are below:

Thursday, September 5

5:30-6:30 pm: "Dispelling LAP-BAND® Myths" Presented by Dr. Jean-Marc Chevallier, Bariatric Surgeon at Hospital European Georges Pompidou, Paris Cedex 15, France and Dr. Jan Willem Greve, Gastrointestinal and Bariatric Surgeon, Zuyderland MC, Heerlen, the Netherlands.

This session will be held at the Novotel Madrid Campo de las Naciones, Calle de Amsterdam, 3, 28042 Madrid, Spain.

About IFSO World Congress 2019

The IFSO World 24^th World Congress, September 3-7, 2019, is comprised of three full days of specialized surgical and integrated health courses. This worldwide congress attracts surgeons from 90+ countries, with nearly 2,500 attendees, and over 400 speakers.

It is the largest worldwide bariatric meeting, usually attended by surgeons, multidisciplinary support staff, researchers, physicians, and other healthcare professionals involved with the main mission of IFSO to unite and educate against adiposity and metabolic disorders. For more details on IFSO World Congress 2019, please visit www.ifso2019.com

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved Lap-Band® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the Lap-Band system, including the risk of default under our security agreement with Apollo Endosurgery entered into in connection with the transaction; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and LAP-BAND system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed May 16, 2019 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACT:

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
949-429-6680 x106
syoungstrom@reshapelifesci.com

or

Debbie Kaster
Investor Relations
Gilmartin Group
415-937-5403
debbie@gilmartinir.com

SOURCE: ReShape Lifesciences Inc.